Zobrazeno 1 - 10
of 50
pro vyhledávání: '"Jaakko Aaltonen"'
Autor:
Aino Vesikansa, Juha Mehtälä, Jaakko Aaltonen, Riikka Konttinen, Kaisa Tasanen, Laura Huilaja
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Introduction and aimPsoriasis vulgaris is associated with a significant healthcare burden, which increases over time as the disease progresses. The aim of this retrospective, population-based registry study was to characterize healthcare resource uti
Externí odkaz:
https://doaj.org/article/50a99801544044c5b47cab289e80baaa
Autor:
Liisa Ukkola-Vuoti, Antti Karlsson, Samuli Tuominen, Mariann I Lassenius, Jaakko Aaltonen, Martta Ranta, Mikko Kosunen, Mari Renlund, Anne Lehtonen, Kari Puolakka
Publikováno v:
Scandinavian Journal of Work, Environment & Health, Vol 49, Iss 5, Pp 341-349 (2023)
OBJECTIVES: Patients with idiopathic inflammatory rheumatic diseases (IIRD) often have decreased working capacity resulting in indirect costs. However, data on patients’ short-term sick leave has been limited. This retrospective cohort study evalua
Externí odkaz:
https://doaj.org/article/1fe2515d6f7544aba6353f0faeb0f661
Autor:
Aino Vesikansa, Juha Mehtälä, Marko Pesu, Jaakko Aaltonen, Riikka Konttinen, Kaisa Tasanen, Laura Huilaja
Publikováno v:
Acta Dermato-Venereologica, Vol 103 (2023)
Therapeutic options for psoriasis vulgaris have changed during recent decades with the introduction of biologics. Few nationwide studies are available on psoriasis treatment patterns, and those from Finland predate the use of biologics. The aim of th
Externí odkaz:
https://doaj.org/article/52a46bf952514ac3b8c2745c2927cafb
Autor:
Thomas Rades, Clare J. Strachan, Ulrike Zimper, Jaakko Aaltonen, Keith C. Gordon, Karen Krauel-Goellner
Publikováno v:
Pharmaceutics, Vol 2, Iss 4, Pp 419-431 (2010)
Particle size reduction is a simple means to enhance the dissolution rate of poorly water soluble BCS-class II and IV drugs. However, the major drawback of this process is the possible introduction of process induced disorder. Drugs with different mo
Externí odkaz:
https://doaj.org/article/c95e7ffd81a14bc484ae1325cc58038b
Autor:
Ilkka Vihriälä, Jari Punkkinen, Tero Ylisaukko-oja, Taina Sipponen, Eija Hirsi, Christian Nielsen, Jyrki Tillonen, Markku Pajala, Jouni Silvennoinen, Ville Liukkonen, Mikko Kellokumpu, Jari Jokelainen, Henna Rautiainen, Veikko Moilanen, Hans Henricson, Hannu Sulonen, Mirva Esterinen, Timo Blomster, Kari Toljamo, Klaus Tamminen, Pauliina Molander, Airi Jussila, Jaakko Aaltonen, Juha Kuisma, Petri Mäkelä, Kalle Hakala, Margus Lääne, Kimmo Salminen, Sauli Herrala, Ulla-Maija Suhonen, Mika Puhto, Markku Peräaho, Heikki Nuutinen
Publikováno v:
Scandinavian Journal of Gastroenterology. 53:158-167
Objectives: The efficacy and tolerability of vedolizumab in the treatment of inflammatory bowel diseases (IBD) has been demonstrated in an extensive GEMINI clinical trial programme. Clinical trials represent highly selected patient populations and, t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc9bb6f87c8c3b92c84b454447a30170
https://doi.org/10.1080/00365521.2017.1416160
https://doi.org/10.1080/00365521.2017.1416160
Autor:
Klaus Tamminen, Mikko Kellokumpu, Tero Ylisaukko-oja, Sauli Herrala, Markku Peräaho, Taina Sipponen, Henna Rautiainen, Petri Mäkelä, Jari Jokelainen, Ulla-Maija Suhonen, Heikki Nuutinen, Markku Pajala, Mirva Esterinen, Margus Lääne, Mika Puhto, Christian Nielsen, Jyrki Tillonen, Veikko Moilanen, Juha Kuisma, Ville Liukkonen, Kalle Hakala, Pauliina Molander, Hannu Sulonen, Saku Torvinen, Jaakko Aaltonen, Jouni Silvennoinen, Hans Henricson, Ilkka Vihriälä, Eija Hirsi, Kari Toljamo, Airi Jussila, Jari Punkkinen, Timo Blomster, Kimmo Salminen
Publikováno v:
Biologicals : journal of the International Association of Biological Standardization. 58
Limited data is available on vedolizumab combination therapies in real-world clinical practice. Here, we evaluated the concomitant corticosteroid, immunosuppressive, and 5-aminosalicylic acid utilization of inflammatory bowel disease (IBD) patients t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68e3e084581707aa9c9a3ddfb0c44882
https://pubmed.ncbi.nlm.nih.gov/30755369
https://pubmed.ncbi.nlm.nih.gov/30755369
Publikováno v:
International Journal of Pharmaceutics. 486:121-130
Pharmaceutically relevant properties, such as solubility and dissolution rate, of active pharmaceutical ingredients can be enhanced by cocrystal formation. Theophylline and nicotinamide are known to form cocrystals, for example if subjected to solid-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36d6ed35e10c23963ceb2c677c83cbed
https://doi.org/10.1016/j.ijpharm.2015.03.012
https://doi.org/10.1016/j.ijpharm.2015.03.012
Publikováno v:
Molecular Pharmaceutics. 11:234-242
Milling is an attractive method to prepare amorphous formulations as it does not require the use of solvents and is suitable for thermolabile drugs. One of the key critical quality attributes of milled amorphous formulations is their dissolution beha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e907483d5c5523a12373dde3d3ce5a4e
https://doi.org/10.1021/mp4004145
https://doi.org/10.1021/mp4004145
Autor:
Jaakko Aaltonen, Timo Laaksonen
Publikováno v:
International Journal of Pharmaceutics. 447:218-223
Changes in the solid-state form can occur during dissolution testing of drugs. This can often complicate interpretation of results. Additionally, there can be several mechanisms through which such a change proceeds, e.g. solvent-mediated transformati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d50e5024a0fcbc515caa51f435bd30b
https://doi.org/10.1016/j.ijpharm.2013.03.007
https://doi.org/10.1016/j.ijpharm.2013.03.007
Autor:
Peep Veski, Karin Kogermann, Jaakko Aaltonen, Andres Lust, Andres Meos, Mirja Palo, Jyrki Heinämäki, Ivo Laidmäe
Publikováno v:
European Journal of Pharmaceutical Sciences. 48:47-54
The aim of this study was to gain understanding about the effects of different solid-state forms of a poorly water-soluble piroxicam on drug dissolution and oral bioavailability in rats. Three different solid-state forms of piroxicam were studied: an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d32c7e6bbd07b8e1d0d5d444febabe6e
https://doi.org/10.1016/j.ejps.2012.10.005
https://doi.org/10.1016/j.ejps.2012.10.005